Cancer Cell Panel Screening, a platform involving the screening of test agents on cells with diverse genomic backgrounds, has emerged as a comprehensive tool for oncology therapeutic development. It provides critical insights into the identification of cell lines that exhibit high sensitivity to certain test agents, the exploration of drug mechanisms, and the evaluation of the efficacy of combination therapies.
Our ICECP™ cancer cell panel platform not only streamlines the drug discovery process but also expedites your progression to clinical trials. It provides drug response data for your small molecule or biologic and offers insights into patient stratification. It also serves as a translational biology accelerator, facilitating progress and informed decision-making on the journey to successful drug discovery and optimized clinical outcomes.
ICECP™ cancer cell panel screening allows robust, flexible, and tailored profiling of test agents on 500+ cancer cell lines, encompassing various assays such as 2D proliferation, 3D proliferation, colony formation, and apoptosis, with no assay timeline constraints. For generated drug resistant cell lines, we perform RNA-seq-based bioinformatic analysis to investigate the mechanism. Utilizing our in-house algorithm, we can provide detailed information about differential gene expression, enriched pathway and featured gene profiling.
ICE Bioscience has established a predefined cell panel comprising 170 tumor cell lines, encompassing 21 cancer types. This cell panel can be utilized for screening sensitive cell lines to test agents, explore new indications, and conduct toxicity screening. ICE possesses a bioinformatics team and a cell information database to support all early and late-stage bioinformatics analyses of the cell panel.
Custom Cell Panels: Tailored Solutions
Choose from over 500 human tumor cell lines available in our ICE cell bank, with an ongoing addition of cell lines per month. Collaborators have the flexibility to select specific cell lines of interest from our cell bank to create a tailored Cell Panel for screening.
✅ Selection of Highly Responsive Tumor Cell Lines: Identify and select tumor cell lines that exhibit the highest responsiveness to your test agents, forming a solid foundation for in-depth research, including cellular models and CDX studies.
✅ Exploration of New Indications: Uncover novel cancer indications for existing drugs, or identify potential anti-cancer applications for drugs from different therapeutic areas in repurposing initiatives.
✅ Genomic Signature Analysis: Optionally, we can analyze your drug's genomic signature to predict its response as an anticancer treatment.
ICE Bioscience has established over 900 cell lines, including 500+ human tumor cell lines covering more than 30 cancer types, such as lung cancer, lymphoma, gastric cancer, breast cancer, prostate cancer, colorectal cancer, and more. Additionally, we have developed 30+ drug-resistant cell lines and 300+ BaF3 kinase cell lines, with ongoing efforts to expand the platform.
Learn more about our other cells panels based on research area.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
